359 related articles for article (PubMed ID: 15795933)
41. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
42. Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment.
Leoni V; Solomon A; Kivipelto M
Biochem Soc Trans; 2010 Aug; 38(4):1021-5. PubMed ID: 20658997
[TBL] [Abstract][Full Text] [Related]
43. Sialic acid moiety of apolipoprotein E and its impact on the formation of lipoprotein particles in human cerebrospinal fluid.
Kawasaki K; Ogiwara N; Sugano M; Okumura N; Yamauchi K
Clin Chim Acta; 2009 Apr; 402(1-2):61-6. PubMed ID: 19138682
[TBL] [Abstract][Full Text] [Related]
44. Lipoproteins and lipid peroxidation in Alzheimer's disease.
Bassett CN; Montine TJ
J Nutr Health Aging; 2003; 7(1):24-9. PubMed ID: 12679837
[TBL] [Abstract][Full Text] [Related]
45. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease.
Raygani AV; Rahimi Z; Kharazi H; Tavilani H; Pourmotabbed T
Neurosci Lett; 2006 Nov; 408(1):68-72. PubMed ID: 16997467
[TBL] [Abstract][Full Text] [Related]
46. Binding and uptake of A beta1-42 by primary human astrocytes in vitro.
Nielsen HM; Veerhuis R; Holmqvist B; Janciauskiene S
Glia; 2009 Jul; 57(9):978-88. PubMed ID: 19062178
[TBL] [Abstract][Full Text] [Related]
47. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease.
Poirier J
Neurobiol Aging; 2005 Mar; 26(3):355-61. PubMed ID: 15639314
[TBL] [Abstract][Full Text] [Related]
48. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
49. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders.
Cacabelos R; Barquero M; García P; Alvarez XA; Varela de Seijas E
Methods Find Exp Clin Pharmacol; 1991 Sep; 13(7):455-8. PubMed ID: 1784142
[TBL] [Abstract][Full Text] [Related]
50. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
[TBL] [Abstract][Full Text] [Related]
51. Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.
Kar S; Poirier J; Guevara J; Dea D; Hawkes C; Robitaille Y; Quirion R
Neurobiol Aging; 2006 Feb; 27(2):199-210. PubMed ID: 16399207
[TBL] [Abstract][Full Text] [Related]
52. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M
Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145
[TBL] [Abstract][Full Text] [Related]
53. Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4.
Tannenberg RK; Scott HL; Tannenberg AE; Dodd PR
Neurochem Int; 2006 Dec; 49(7):631-9. PubMed ID: 16814428
[TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
55. Reverse modulation of the HDL anionic peptide factor and phospholipid transfer protein activity in coronary artery disease and type 2 diabetes mellitus.
Attia N; Domingo N; Lorec AM; Nakbi A; Hammami S; Ben Hamda K; Portugal H; Lairon D; Hammami M; Chanussot F
Clin Biochem; 2009 Jun; 42(9):845-51. PubMed ID: 19135989
[TBL] [Abstract][Full Text] [Related]
56. Premorbid effects of APOE on synaptic proteins in human temporal neocortex.
Love S; Siew LK; Dawbarn D; Wilcock GK; Ben-Shlomo Y; Allen SJ
Neurobiol Aging; 2006 Jun; 27(6):797-803. PubMed ID: 15979210
[TBL] [Abstract][Full Text] [Related]
57. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls.
Laske C; Stransky E; Leyhe T; Eschweiler GW; Maetzler W; Wittorf A; Soekadar S; Richartz E; Koehler N; Bartels M; Buchkremer G; Schott K
J Psychiatr Res; 2007 Aug; 41(5):387-94. PubMed ID: 16554070
[TBL] [Abstract][Full Text] [Related]
58. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis.
Satoi H; Tomimoto H; Ohtani R; Kitano T; Kondo T; Watanabe M; Oka N; Akiguchi I; Furuya S; Hirabayashi Y; Okazaki T
Neuroscience; 2005; 130(3):657-66. PubMed ID: 15590150
[TBL] [Abstract][Full Text] [Related]
59. Determination of human plasma phospholipid transfer protein mass and activity.
Jauhiainen M; Ehnholm C
Methods; 2005 Jun; 36(2):97-101. PubMed ID: 15893933
[TBL] [Abstract][Full Text] [Related]
60. Expression of APP pathway mRNAs and proteins in Alzheimer's disease.
Matsui T; Ingelsson M; Fukumoto H; Ramasamy K; Kowa H; Frosch MP; Irizarry MC; Hyman BT
Brain Res; 2007 Aug; 1161():116-23. PubMed ID: 17586478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
